ONE-WAYDated event · through FY2023-Q2
In-licensing, clinical development and approval of NS-32
An individual drug development theme concerning NS-32, licensed in from Pharmacosmos, involving the start of a domestic Phase I trial, followed by a Phase III trial and regulatory filing, culminating in approval.
Companies1How many companies write about this.
Threads1One company can carry more than one thread here.
PeriodFY2017-Q3 →Last written FY2023-Q2
Directionhelps1 helps · 0 hurts · 0 flat